This edition of the Global Fund PSD Newsletter contains
In 2013, The Global Fund to Fight AIDS, Tuberculosis and Malaria launched a new funding model (NFM), aiming to ensure that Global Fund grants reach areas of greatest need and achieve the highest possible impact against the three diseases. The process countries undertake to develop programs and access funding was re-designed to be more inclusive, predictable and flexible than the previous model. With the NFM’s new ways of working come new opportunities and challenges for Global Fund partners, including the private sector.
But what exactly does the new model mean for the private sector? Have opportunities for companies to partner with the Global Fund or to contribute to the fight against AIDS, TB and malaria changed? Read the Private Sector Guide to the Global Fund NFM to find out.
July 20-25, 2014 | Melbourne, Australia
The 20th International AIDS Conference (IAC), themed Stepping up the Pace, presented new scientific knowledge and opportunities for structured dialogue on the major issues facing the global response to HIV. High-level speakers included former U.S. President Bill Clinton, UNAIDS Executive Director Michel Sidibé, and activist and artist, Sir Bob Geldof.
Private sector initiatives and Global Fund corporate partners, including Chevron, BHP Billiton, Oil Search, Abt Associates and others, were highlighted in a number of sessions. Read more about IAC and private sector representation here.
The private sector is represented on the Finance and Operational Performance Committee (FOPC) by Advisory Group member Nazzareno (Naz) Todini (Chief of Party, Health Finance and Governance Project, Abt Associates), who was appointed to the role in May 2014. Mr. Todini brings strong experience in international public health and financial management to the Committee, and will serve a two-year term, through the end of the 36th Board Meeting in 2016.
“Abt Associates has been a dedicated and valuable member of the PSD for many years, and we are excited to have Naz representing the private sector on this important Committee, given his considerable expertise and experience,” said Paul Schaper, PSD Board Member. “The private sector brings particular skills to the FOPC and a strong voice to help shape the Committee’s work. Over the coming two years, the FOPC will be addressing several critical issues, including oversight of the Global Fund’s new financial management policy, the operation of the new funding model, improved risk management, and the Fund’s performance evaluation framework.”
September 29, 2014 | Yangon, Myanmar
Malaria elimination and control in Asia-Pacific is a crucial public health issue. Emerging parasite resistance to drugs and insecticides threaten to compound an already challenging epidemic. As the region readies for an economic boom in countries such as Myanmar and Viet Nam, there is a real threat of losing the gains made against malaria and significant losses in human capital and resources unless action is taken now. Recognizing that corporate participation is essential to malaria control and elimination efforts, regional and global partners will convene a private sector-focused forum in Yangon, Myanmar in late September.
The forum will be hosted by Asia Pacific Leaders Malaria Alliance (APLMA), Roll Back Malaria Partnership and GBCHealth, in partnership with The Global Fund to Fight AIDS, Tuberculosis and Malaria, Malaria No More and Myanmar Health and Development Consortium, and with the support of Sanofi. Bringing together local, regional, and multi-national private sector companies, government representatives, Chambers of Commerce, bi-lateral and multi-lateral development partners, the event will aim to catalyze private sector action to address malaria challenges including resistance, stimulate cross-sector collaboration for workplace and community initiatives and expand the reach and impact of region-wide malaria efforts such as WHO’s Emergency Response to Artemisinin Resistance and the Global Fund’s Regional Artemisinin Initiative in the Mekong Region.
For more information on the event, please contact Fareeda Ehtesham at firstname.lastname@example.org.
The 2014 Annual PSD Retreat will focus on setting strategic priorities for the coming year and discussing PSD positions on key Global Fund issues. The group will evaluate effectiveness and results of the internal taskforce structure put in place last year, discuss priorities for strengthening private sector partnership with the Fund, including under the new approach to funding, and prepare for the upcoming Board Retreat and 32nd Board Meeting in Montreux, Switzerland scheduled for mid-November. The meetings are open to PSD Advisory Group and Affiliate members only. Contact email@example.com for more information.
The Global Fund to Fight AIDS, Tuberculosis and Malaria recently launched the Innovation Coalition, a global, multi-sector partnership platform designed to draw on the innovations, creative energy and solution-oriented approaches of private sector companies, academia and civil society to help solve recurring challenges encountered by Global Fund grant recipients. The Innovation Coalition will identify high-impact opportunities to strengthen grant performance, determine how private sector collaboration can unlock effective solutions, and pilot these innovative approaches together with multi-sector partners.
Leading private sector companies from across industries, including consumer goods, healthcare and pharmaceutical products, transportation, logistics, insurance, banking, and information and communication technology, have already joined the Innovation Coalition. Read more about the Global Fund’s Innovation Coalition and how your company can get involved.
CAMA brings the collective force and voice of the private sector to improve the impact of malaria control and elimination efforts in Africa by promoting multi-company and multi-sector partnerships, exchanging knowledge and best practices, and building country-level capacity for effective malaria control and elimination. GBCHealth serves as the Secretariat for CAMA. Learn more here.
The Private Sector Constituency (PSC) to the Roll Back Malaria Partnership (RBM) published its bi-annual Newsletter in June 2014. The Newsletter provides a summary of key decisions taken at the RBM’s 26th Board meeting (Geneva, May 2014). The PSC elected new leadership: Jon Pender (GlaxoSmithKline) and Lisa Goldman-Van Nostrand (Sumitomo Chemical) as Board Members, and Nancy Nachbar (Abt Associates) and Sherwin Charles (Nando’s) as Alternates. The Newsletter also summarizes the process to develop the second iteration of the Global Malaria Action Plan and offers private sector perspectives on drug and insecticide resistance. Read the Newsletter here.
In May, the Global Fund received 43 expressions of interest (EOIs) from regional applicants for proposals totaling $689 million, far exceeding the $120 million envelope set for the 2014 window. Programs will be screened for eligibility and technical soundness by the independent Technical Review Panel and the Secretariat’s Grant Approval Committee, after which successful proposals will be allocated an indicative funding amount and invited to submit fully-developed concept notes.
The May deadline was the first milestone in the new process for regional applications approved by the Global Fund Board in March of this year. Implemented across multiple countries, regional programs use interventions that can have a greater impact through cross-border and multi-country collaboration. There will be a second opportunity for regional EOIs to be submitted in April 2015, when an additional $80 million will be available.
The majority of EOIs were from sub-Saharan Africa, with 20 applications for a total of $431 million. Over two-thirds of the EOIs focused on HIV/AIDS – 29 submissions amounting to $347 million. TB programs were the second-most numerous, with 8 submissions amounting to $222 million, while submissions for malaria totaled 5 and $84 million. Private sector organizations were included as key partners in several submitted EOIs, including a proposal to implement sustainable, scalable TB care through the private sector in Asia, and a proposal to address the prevalence of TB among mining communities in Southern Africa.
GBCHealth announced the appointment of Nancy Wildfeir-Field as its new President, effective June 2, 2014. Nancy brings to GBCHealth extensive international experience in both global health and the private sector, having most recently served as Director, Global Partnerships for BSR (Business for Social Responsibility). Nancy also held positions with USAID in the Caribbean and Eastern Europe, The Prince of Wales International Business Leaders Forum (IBLF) and Burson-Marsteller, and worked as a consultant to the UK Ministry of Health. The appointment follows the departure of Michael Schreiber, Executive Director.
“Nancy’s rich and diverse experience will allow her to drive GBCHealth forward as the world’s foremost expert on business engagement in global health,” said Ray Chambers, Co-Chair of the GBCHealth Board. “With fewer than 500 days remaining to achieve the MDGs and a need to protect hard-won health progress beyond 2015, Nancy’s leadership in harnessing business resources for global health goals will be vitally important.”
Wildfeir-Field underlined the importance of the PSD and the Global Fund, stating, “Private sector engagement is increasingly important in affecting solutions to some of the world’s most complex issues. The PSD has an impressive track record on issues across the Global Fund’s portfolio. The work of the PSD and the Global Fund remains central to GBCHealth’s strategic priorities, as we work with companies to address key health issues and to maximize results and impact.”
Johnson & Johnson became the newest company to join the PSD Advisory Group in April 2014. Johnson & Johnson will be represented on the PSD by its subsidiary, Janssen Global Public Health, a company dedicated to improving access to and affordability of drugs, identifying and developing vaccines, diagnostics, and medicines to address neglected diseases and unmet medical needs. Janssen recently introduced a new treatment option for MDR-TB. Through public-private partnerships in R&D, differentiated pricing and collaborations around responsible use and distribution, Janssen is working to ensure the product is accessible in countries where it is approved for use.
“We welcome Johnson & Johnson as the newest member and look forward to their contributions to the PSD. Our PSD members share a common goal of ensuring high quality health access to all people being supported by the Global Fund, and it is a pleasure to have Johnson & Johnson join this collective dialogue,” said Renuka Gadde, Alternate Board Member for the PSD.
Jami Taylor, Senior Director for Global Access Policy at Janssen Global Public Health, will represent Johnson & Johnson on the Advisory Group and in the PSD’s Health Systems Strengthening taskforce.
ELI LILLY: Eliminating Mother-to-Child Transmission of HIV in Nigeria
Most TB drugs currently approved for treatment are 50+ years old and are required to be taken over a 6-month period to be effective. Compliance with such a long treatment regimen is a challenge, limiting drugs’ effectiveness and contributing to the rise in MDR-TB. As part of its MDR-TB Partnership, Eli Lilly and Company formed innovative partnerships with the Infectious Disease Research Institute (IDRI) and the Bill and Melinda Gates Foundation to discover new and more effective TB drugs. These partnerships draw on the expertise of private sector companies like Lilly and seek multi-sector solutions to accelerate progress in the fight against TB. Read more about Lilly’s innovative partnerships here.
UPCOMING MEETINGS AND EVENTS
12th Finance and Operational Performance Committee Meeting
69th United Nations General Assembly
New York, United States
Opportunities for Corporate Sector Engagement in Malaria Control in Asia-Pacific: Forum and Reception
13th Strategy Investment and Impact Committee Meeting
10th Audit and Ethics Committee Meeting
4th Annual PSD Retreat
1st Annual RBM Private Sector Retreat
London, United Kingdom
Global Fund Board Retreat
PSD Pre-Board Meeting
32nd Global Fund Board Meeting
ADVISORY GROUP NEWS
More Advisory Group News here.
GLOBAL FUND NEWS AND UPDATES
31 July 2014
17 July 2014
24 June 2014
19 June 2014
13 June 2014
20 May 2014
09 May 2014
22 April 2014
10 April 2014
09 April 2014
07 April 2014
02 April 2014
Board Member: Paul Schaper, Executive Director, Global Public Policy, Merck & Co./MSD
Alternate Board Member: Renuka Gadde, Vice President, Global Health, BD
Advisory Group Members
GBCHealth is the Focal Point for the Private Sector Delegation to the Global Fund, working with the committed companies of the Advisory Group to steer Global Fund priorities and policies, while also ensuring that the Global Fund actively engages the business sector.
For more information on how your company or private sector organization can get involved, please contact PSD Focal Point, Whitney White at firstname.lastname@example.org. Learn more about the Private Sector Delegation.